To circumvent these obstacles, several groups, including Dheilly et al. [243] have developed bispecific antibodies that target CD47 with lower affinity alongside other tumor specific antigens, to achieve tumor-specific CD47 blockade, which spares red blood cells [243]. The gene discussed is CD47; the disease is neoplasm.